Vaxxas announced today that it has received a $22 million award from the Biomedical Advanced Research and Development Authority (BARDA) at U.S. HHS to support a clinical study involving the company’s vaccine-delivery patch. The money will mostly pay for a Phase 1 clinical study in which Vaxxas’ high-density micro-array patch (HD-MAP) delivering pandemic influenza vaccine […]
Funding Roundup
Enable Injections completes $25M credit facility
Enable Injections announced today that it completed a credit facility worth $25 million from Oxford Finance LLC. Cincinnati-based Enable Injections said in a news release that the funds are earmarked for supporting the scaling of high-volume manufacturing and the achievement of major inflection points as it moves toward commercialization. The company develops the enFuse, a […]
CureVac stock soars after $213.3M IPO
Shares of CureVac (NSDQ:CVAC) continue to rise after the company reportedly raised $213.3 million in its initial public offering on Friday. According to a report from MarketWatch, the Germany-based biotech outfit priced its IPO at $16 per share and sold more than 13.3 million shares to raise the $213.3 million. Currently, shares of CVAC are […]
Inovio to scale up production of smart delivery device for potential COVID-19 vaccine
Inovio Pharmaceuticals (NSDQ:INO) announced that it received $71 million from the U.S. Defense Dept. to support its Cellectra 3PSP smart device. Funding from the DoD is set to support large-scale manufacturing for the Cellectra 3PSP and the procurement of Cellectra 2000 devices, which are used to deliver Inovio’s INO-4800 COVID-19 vaccine candidate directly into the skin. […]
Smiths Medical lands major vaccine-related contract
Smiths Medical announced today that it has landed a federal contract to produce more than 78 million syringe-and-needle units and $20 million in federal funding to expand its Keene, N.H. plant to produce them. The Plymouth, Minn.-based company said it received an order for 78.6 million syringe-and-needle units and that BARDA and the Joint Program […]
Bigfoot Biomedical raises $55m in Series C
Diabetes treatment tech company Bigfoot Biomedical announced today that it raised $55 million to close its Series C financing round. Abbott (NYSE:ABT) led the funding round with participation from new investor Smile Group and existing investors Quadrant Capital Advisors, Senvest Capital, Janus Henderson and Cormorant Asset Management. Get the full story at our sister site, MassDevice.
Ocular Therapeutix commences public offering
Ocular Therapeutix (NSDQ:OCUL) announced that it commenced an underwritten public offering of an undisclosed amount of its common stock. The Bedford, Mass.-based eye condition therapy developer filed with the SEC to confirm the offering with the shares at a par value of $0.0001 per share. The common stock at market close on May 18 prior to the announcement […]
Rani Therapeutics could go the IPO route
Rani Therapeutics is reportedly moving forward with an early-stage efficacy and safety study for its robotic pills and may be on its way toward the possibility of an IPO. According to a report in Endpoints News, Rani, led by CEO Mir Imran who shared the story on LinkedIn, revealed that its RaniPill performed as expected […]
Vascular Therapies closes $17.3m financing
Vascular Therapies announced that it closed an upsized private funding round worth more than $17 million with contributions from new and existing investors. The Cresskill, N.J.–based clinical-stage biopharma company originally targeted $15 million for the financing, but finished with a total of $17.3 million raised. Get the full story at our sister site, MassDevice.
CF PharmTech raises $90m
Pharmaceutical company CF PharmTech, which focuses on respiratory treatments, announced today that it raised $90 million in a Series E financing round. Shuzhou, China–based CF PharmTech said the latest round of funding reflects strong support from China’s investors and will allow the company to bring new products from its pipeline to market. The company produces […]
